Sunitinib as a Second-Line Therapy in Patients With Metastatic RCC After Immune Checkpoint Inhibitor–Based Combination Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
ESMO Open 2022 Apr 08;7(2)100463, E Grande, T Alonso-Gordoa, O Reig, E Esteban, D Castellano, X Garcia-Del-Muro, MJ Mendez, J García-Donas, M González Rodríguez, JA Arranz-Arija, P Lopez-Criado, J Molina-Cerrillo, B Mellado, C Alvarez-Fernandez, G De Velasco, MA Cuéllar-Rivas, RM Rodríguez-Alonso, JF Rodríguez-Moreno, C Suarez-RodriguezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.